Relation between chronic prostatitis and prostate cancer

Abstract

The mechanism and etiology of prostate cancer development has not been clearly established up to date. The discovery of prostate specific antigen (PSA) has become a cornerstone in the prostate cancer diagnosis. PSA is an important organ specific tumor marker, however, it is not cancer specific. It is well known that hystopathologic changes develop in tissues where inflammation occurs. Infection and inflammation are complex response in which several pathways play role and some of these pathways are activated during the cancer process, as well. Chronic inflammation and chronic infections play important role in carcinogenesis of various organ (such as bladder, liver, colon, esophagus and stomach) and are considered to be etiologic
factors in about 20% of cancers. Epidemiologic, hystologic and genetic studies suggests that there may be a relation between common conditions such as prostatitis and prostate cancer. As a conclusion, the conditions that trigger and sustain the inflammatory process may be very important for prostatic carcinogenesis.

Keywords

• Chronic prostatitis
• prostate cancer
• inflamation
• tissue damage

Prostat Kanseri Gelişimi İçin Kronik prostatit Bir Risk Faktörü müdür?

Abstract

Bu güne kadar prostat kanseri gelişimine sebep olabilecek nedenler ve mekanizmalar bütün açıklığı ile ortaya konulamamıştır. Wang Prostat Spesifik Antijeni (PSA) keşfetmiştir. PSA önemli bir tümör belirtecidir ancak organa özgü olmasına karşın kansere özgü değildir. Vücutta meydana gelen enflamatuvar durumlarda enflamasyonun meydana geldiği yerdeki dokuda histopatolojik değişikliklerin ortaya çıktığı bilinmektedir. Enflamatuvar sürecin diğer bazı tümörlerde olduğu gibi, prostatik karsinogenezde de önemli bir yeri olduğunu düşündüren bilimsel veriler mevcuttur. Buna göre enfeksiyona bir cevap olarak dokuda reaktif oksijen ve nitrojen türleri oluşmakta ve oluşan bu ürünler hücrede DNA hasarına yol açmaktadırlar. Kronik enflamasyonun gerek doku hasarı gerek enflamatuvar süreçte ortaya çıkan mediatörler aracılığı ile kanser gelişiminde rol oynayabileceği gittikçe artan araştırmalar ile ortaya konulmaktadır. Sonuçta, enflamatuvar süreci tetikleyen, idame ettiren koşullar prostatik karsinogenez açısından çok önemli olabilirler.

Keywords

• Kronik prostatit
• prostat kanseri
• enflamasyon
• doku hasarý

References

1. Wang MC, Valenzuela LA, Murphy GP. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
2. Papsidero LD, Wang MC, Valenzuela LA. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980;40:2428-2432.
3. Kuriyama M, Wang MC, Papsidero LD. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40:4658-4662.
4. Jemal A, Siegel R, Ward E, et al. Cancer statics, 2006. CA Cancer J Clin 2006;56:106-30.
5. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum PSA values. J Urol 1994;151(6):1571-4.
6. Akdaþ A, Çevik I, Tarcan T, Turkeri L, Dalaman G, Emerk K. The role of free prostate specific antigen in the diagnosis of prostate cancer. Brith J Urol 1997;79(6):920-923.
7. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 2005;173(6):1969-74.
8. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stres in human carcinogenesis. Int J Cancer 2007;121:2381- 6.

9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7.
10. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol. 2007;25(5):398-400.
11. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund- Johansen T, Naber KG, Hartung R, Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma.BJU Int. 2007;100(4):733-7.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-69.
13. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91(3):459-77.
14. Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989;33(6): 465.
15. Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000;82(3): 718- 25.
16. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002;13(1):72-9.
17. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60(1):78-83.
18. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171:S36- 40
19. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2160-6.
20. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high- grade prostatic intraepithelial neoplasia. Urology. 2000;56(5):828-32.
21. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158(5):1767-73.
22. Al Marhoon M. Is There a Role for Helicobacter Pylori Infection in Urological Diseases? Urol J 2008;5(3):139- 43.
23. Ferrero Doria R, Perez Flores D, Terrer Artes C, Guzman Martinez-Valls PL, Morga Egea JP, Tomas Ros M, et al. Impact of prostatic benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels. Actas Urol Esp 1997;21(2):100- 104.
24. Hochreiter WW, Duncan JL, Schaeffer AJ. Evaluation of the bacterial flora of the prostate using a 16S rRNA gene based polymerase chain reaction. J Urol 2000;163(1):127-30.
25. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Eur Urol 2008 Dec;54(6):1379-84.
26. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159(6):2159-65.
27. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361):955- 64.
28. Bakhle YS. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001;134(6):1137-50.
29. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470(2): M69-78.
30. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1108-11.
31. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9(1):119-23.
32. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal antiinflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7(1): 169-70.
33. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42(1):73-8.
34. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 2001;61(24):8617-23.